BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Altor BioScience Corporation Introduces STAR(TM) Multimer Reagents To Measure Disease-Specific Antigen Presentation


3/13/2006 11:49:41 AM

MIRAMAR, Fla., March 13 /PRNewswire/ -- Altor BioScience Corporation today announced the introduction of first-in-class Soluble T-cell Antigen Receptor (STAR(TM)) Multimer reagents that enable accurate measurement of tumor and viral peptide antigen presentation on diseased cells and tissues.

The new products based on Altor's proprietary technologies comprise soluble recombinant T-cell receptors that recognize different peptide epitopes of the oncogenic protein p53 and the cytomegalovirus (CMV) pp65 polypeptide in the context of HLA-A2.1. The p53-specific STAR(TM) Multimers can be used as research tools to validate, quantify or monitor the display of p53 peptide/HLA-A2.1 complexes on antigen presenting cells, tumor cells and tissues. Since half of all tumors overexpress p53, these reagents will enable investigators to better understand and develop new diagnostic and therapeutic approaches for a broad range of cancers. CMV pp65-specific STAR(TM) Multimers can be used by researchers to examine changes in antigen presentation occurring during acute and chronic viral infection. STAR(TM) Multimers are available in reagent and kit formats for use in standard flow cytometry and immunohistochemistry methods.

Hing Wong, Ph.D., CEO of Altor, commented, "We are very pleased to be able to offer these break-through products to the research community. We believe that our current STAR Multimers have the potential to advance drug and vaccine development, as well as to contribute to basic and clinical research in a number of important medical conditions. Our intention is to rapidly expand our reagent portfolio to cover multiple epitopes derived from other human tumor antigens and viruses such as HIV and HCV."

Dr. Wong and his team have published an article in the March 1, 2006 issue of Journal of Immunology describing the exquisite sensitivity and specificity of p53-specific STAR(TM) Multimers. The study also demonstrated use of these reagents in simple staining procedures to differentiate human tumors from normal tissues. Altor intends to employ STAR(TM) Multimers to identify patients likely to benefit from its TCR-based targeted approaches for treating cancer. Altor's lead drug candidate is expected to enter clinical development later this year.

About Altor BioScience

Altor BioScience Corporation is a product-oriented biotechnology company engaged in research and development of novel diagnostic and therapeutic approaches for cancer, viral infections and autoimmune diseases. Altor's most advanced products include TCR-based therapeutics targeting a variety of different cancers. For more information, visit http://www.altorbioscience.com .

Altor BioScience Corporation

CONTACT: Peter Rhode, Ph.D., Altor BioScience Corp., +1-954-443-8600, orpeterrhode@altorbioscience.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES